Identification of plasma-derived exosomal miRNAs as potential predictors for anti-PD-1 therapy in patients with lung cancer
| Top 10 DE miRNAs | logFC | logCPM | P value | FDR |
| hsa-miR-320d | 2.478246 | 7.953041 | 8.56E-05 | 0.050411 |
| hsa-miR-642a-3p | 4.429584 | 2.612111 | 0.000513 | 0.102554 |
| hsa-miR-320c | 1.919471 | 9.497452 | 0.000522 | 0.102554 |
| hsa-miR-320b | 1.678455 | 10.70763 | 0.001134 | 0.167017 |
| hsa-miR-200a-3p | 2.024362 | 5.74316 | 0.003509 | 0.370143 |
| hsa-miR-365a-3p | 4.031761 | 1.961358 | 0.004822 | 0.370143 |
| hsa-miR-365b-3p | 4.032808 | 1.961358 | 0.004948 | 0.370143 |
| hsa-miR-4662a-5p | −2.83216 | 3.325355 | 0.005027 | 0.370143 |
| hsa-miR-10a-3p | 2.697804 | 4.247801 | 0.008292 | 0.542682 |
| hsa-miR-6511b-3p | −2.55458 | 3.294422 | 0.011099 | 0.653718 |
Differentially expressed (DE) miRNAs between PD and PR patients were analyzed by exact test (logCPM>4, p<0.05, FDR≤0.1).
CPM, counts per million; FC, Fold change; FDR, false discovery rate; PD, progressive disease; PR, partial response.